Altamira Therapeutics Ltd
CYTO
CYTO was delisted on the 19th of December, 2024.
3 hedge funds and large institutions have $3.47K invested in Altamira Therapeutics Ltd in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
25% less funds holding
Funds holding: 4 → 3 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
87% less capital invested
Capital invested by funds: $26.7K → $3.47K (-$23.3K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.72K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$23.7K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$3 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| $3.44K | +$1.72K | +809 | +95% |
|
2
Group One Trading
Chicago,
Illinois
| $29 | – | – | – |
|
|
LI
3
LRI Investments
Palm Beach Gardens,
Florida
| $2 | +$2 | +1 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| – | -$23.7K | -6,814 | Closed |
|
|
5
Wells Fargo
San Francisco,
California
| – | -$3 | -1 | Closed |
|
CYTO Hedge Fund Activity: Q1 2024 in Review
3 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q1 2024, worth a combined $3.47K — down 87% from $26.7K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CYTO and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $1.72K. The largest seller was UBS Group, exiting entirely with an estimated $23.7K sold.
- 3 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q1 2024, down from 4 in Q4 2023.
- Funds reported $3.47K of Altamira Therapeutics Ltd stock for Q1 2024, down 87% quarter-over-quarter.
- 1 fund opened new Altamira Therapeutics Ltd positions in Q1 2024 and 2 closed out, a net change of -1 holder.
- The largest Altamira Therapeutics Ltd buyer in Q1 2024 was Tower Research Capital (TRC), an estimated $1.72K added.
- The largest Altamira Therapeutics Ltd seller in Q1 2024 was UBS Group, an estimated $23.7K sold.
Based on aggregated 13F filings for Q1 2024.